Technical Information about 8-Br-cAMP-AM

Membrane-permeant, metabolically activatable stimulator of cAMP-dependent protein kinase type I & II and of Epac

Update: October 27, 2009 AI



Abbreviation: **8-Br-cAMP-AM**

Formula	CAS No.	Molecular Weight	UV	BIOLOG Cat. No.
$C_{13}H_{15}BrN_5O_8P$	[190522-24-8]	480.2	λ_{max} 264 nm; ε 17000 / pH 7	B 020

Name: 8- Bromoadenosine- 3', 5'- cyclic monophosphate, acetoxymethyl ester

Description: 8-Br-cAMP-AM is an analogue of the natural signal molecule cyclic AMP in which the hydrogen in position 8 of the heterocyclic nucleobase is replaced by bromine and the polar cyclic phosphate is masked by an acetoxymethyl group.

Properties: The acetoxymethyl group of 8-Br-cAMP-AM masks the charged polar phosphate and thus makes the molecule highly membrane-permeant. Inside the cell esterases release the more polar PKA activator 8-Br-cAMP (Cat. No. B 007) which is thus accumulated. 8-Br-cAMP-AM is especially useful if 8-Br-cAMP is too polar for direct application.
Phosphate tris(acetoxymethyl)ester, PO_4-AM_3 (Cat. No. P 030), is recommended as control reagent in 8-Br-cAMP-AM applications to test for side effects of enzymatically released acetic acid and formaldehyde, two metabolites with potential biological functions.

Specification: Lyophilized or crystallized solid. Please note that equal concentrations of 8-Br-cAMP-AM can appear very different in volume due to sensitivity of the lyophilized form to humidity. Micromolar quantities are determined by UV at λ_{max}.

Purity: Typical analysis is better than 97% (HPLC / UV / 264 nm) for the mixture of equatorial and axial isomers. The product is not sterile and has not been tested for endotoxins.

Solubility/Application: Due to its rather high lipophilicity, the solubility of 8-Br-cAMP-AM in water or buffers is limited. We suggest to use a small amount of anhydrous organic solvent such as anhydrous DMSO or DMF for dissolution at 1-100 mM, and to dilute with water or buffer down to the concentrations required. In some cases, especially at high concentrations (~ 1 mM), Pluronic® F-127 (Molecular Probes) can be useful to facilitate solubilization in physiological media. Please keep in mind that due to the high potency of 8-Br-cAMP-AM relatively low concentrations (0.005-0.1 mM) should be sufficient, and be sure to check for DMSO/DMF tolerance in your system. Since 8-Br-cAMP-AM is bioactivated by esterases, application to cell cultures should be performed without serum supplements (even heat-inactivated serum still contains active esterases!) in the media for at least 15 minutes. Otherwise, serum esterases may strongly reduce the cell-loading efficacy. Please rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing.

Stability and Storage: 8-Br-cAMP-AM is sufficiently stable to be shipped at ambient temperature, however, it should be stored in the freezer (-20°C necessary, -80°C recommended). Please note that aqueous solutions are rather labile and should be freshly prepared immediately before use. Stock solutions in anhydrous DMSO or DMF should be relatively stable when stored frozen at -20°C to -80°C.

BIOLOG Life Science Institute, Bremen, Germany Phone: 49 (0) 421 591355 Fax: 49 (0) 421 5979713 e-mail: service@biolog.de

Toxicity and Safety: Since cyclic AMP has multiple tasks in every organism it is very likely that lipophilic cAMP analogues will interfere with many cell regulation processes *in vivo*. However, due to the rather small quantities to work with no health hazards have been reported. Nevertheless please keep in mind that the *in vivo* properties of this compound are not sufficiently characterized up to now. Avoid skin contact or ingestion and allow only trained personnel to handle the product.
Our products are designed, developed and sold for research purposes only. They are intended for *in vitro* and nonhuman *in vivo* laboratory applications. Any other use requires approval of health authorities.
Not for drug, household or related uses!

Selected References for 8-Br-cAMP-AM:

Moll, D.; Prinz, A.; Gesellchen, F.; Drewianka, S.; Zimmermann, B.; Herberg, F.W., *J. Neural. Transm*., **113**, 1015 - 1032 (2006): "Biomolecular Interaction Analysis in Functional Proteomics"

Krakstad, C.; Christensen, A. E.; Døskeland, S. O., *J. Leukoc. Biol*., **76**, 641 - 647 (2004): "cAMP Protects Neutrophils Against TNF-alpha-induced Apoptosis by Activation of cAMP-dependent Protein Kinase, Independently of Exchange Protein Directly Activated by cAMP (Epac)"

Kruppa, J., Keely, S., Schwede, F., Schultz, C., Barrett, K.E. and Jastorff, B., *Bioorg. Med. Chem. Lett*. **7**, 945 - 948 (1997): "Bioactivatable Derivatives of 8-Substituted cAMP- Analogues"

BIOLOG Life Science Institute, Bremen, Germany Phone: 49 (0) 421 591355 Fax: 49 (0) 421 5979713 e-mail: service@biolog.de